Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tumor Image-Guided Platform R&D Deemed Critical To Therapy Effectiveness

This article was originally published in The Gray Sheet

Executive Summary

"Real-time" cancer imaging modalities will allow more targeted drug and biologic treatment delivery to tumor sites, cancer researchers agreed at the Radiological Society of North America annual meeting Nov. 29

You may also be interested in...



Fusion Imaging Software May Circumvent Need For Dual-Modality Devices

Future applications of fusion imaging will permit viewing of coronary artery disease, end-organ perfusion abnormality and wall-thickening abnormality in a single picture, University of New Mexico radiologist Michael Hartshorne, MD, said Nov. 29

Fusion Imaging Software May Circumvent Need For Dual-Modality Devices

Future applications of fusion imaging will permit viewing of coronary artery disease, end-organ perfusion abnormality and wall-thickening abnormality in a single picture, University of New Mexico radiologist Michael Hartshorne, MD, said Nov. 29

InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required

FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel